Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
An open, single-center Phase I trial to assess the safety, tolerability and immunogenicity of two ascending doses of the candidate vaccine MVA-SARS-2-S

Proposed period of release:
01/10/2020 to 31/03/2021

Name of the Institute(s) or Company(ies)
Universitätsklinikum Hamburg-Eppendorf (UKE), ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Recombinant Modified Vaccinia Virus Ankara (MVA) delivering the S-glycoprotein of the
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), manufactured on chicken
fibroblast cell line DF-1: MVA-SARS-2-S.

Genus: Orthopoxvirus
Species: Vaccinia virus

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
-Orthopoxvirusvaccinia-Modified vaccinia virus Ankara-

European Commission administrative information

Consent given by the Member State Competent Authority:
03/09/2020 00:00:00